DMD and Duchenne muscular dystrophy: AOs with 2′-O-methyl-phosphorothioate RNA (2′-OMePS) and Phosphorodiamidate morpholino oligomer (PMO) chemicals have been widely deployed for exon-skipping in dystrophin transcripts and applied in clinical trials for DMD treatment [7,8,9,10,11].